PET-CT predicts lymphoma survival better than conventional imaging

September 17, 2014, Lancet

Positron emission tomography/computed tomography (PET-CT) is more accurate than conventional CT scanning in measuring response to treatment and predicting survival in patients with follicular lymphoma, and should be used routinely in clinical practice, according to new research published in The Lancet Haematology.

"Our findings have important implications for patients with , a common and usually slow-growing lymphoma. Compared to conventional CT scanning, PET-CT is more accurate in mapping-out the lymphoma, and better identifies the majority of patients who have a prolonged remission after treatment", explains Professor Judith Trotman, study leader and Associate Professor at Concord Hospital, University of Sydney, Australia.

Almost all patients with follicular lymphoma, a common type of non-Hodgkin lymphoma, respond very well to initial treatment with immunochemotherapy, but relapse is common. Current practice is to use CT imaging to evaluate treatment response. However CT cannot easily distinguish patients who are likely to remain in a prolonged remission for several years from those at high risk of early relapse. This creates considerable uncertainty for patients.

PET-CT is performed using a very small amount of a tracer called 18F-fluorodeoxyglucose (FDG)—glucose containing a radioactive tag—which is injected into the patient. The FDG is highly concentrated in and so the PET-CT scan will light-up in areas of lymphoma activity. An important goal of therapy is to 'switch-off' these lighted areas, obtaining a PET-negative remission.

By assessing imaging performed in three clinical trials, Dr Trotman and her French and Italian colleagues examined the link between PET-CT status and survival following first-line immunochemotherapy for advanced follicular lymphoma. Independent, masked reviewers evaluated the scans of 246 patients who underwent both PET-CT and traditional CT imaging within 3 months of their last dose of therapy.

The predictive power of PET-CT was much stronger than conventional CT, accurately identifying patients with an unfavourable prognosis—a PET-positive population with a high rate of disease progression and an almost seven fold increased risk of death—in whom the cancer should be closely monitored. PET-CT also identified that the 83% of patients who achieved PET-negativity had a reassuringly favourable prognosis, with average remission duration beyond 6 years.

According to Prof Trotman, "Our study shows that PET-CT is much better in evaluating treatment response and is an early predictor of survival. This greater accuracy will assist physicians to more effectively monitor their patients. We expect this research will result in PET-CT imaging replacing CT, becoming the new gold standard to evaluate patients with follicular lymphoma after treatment. Importantly, it will be a platform for future studies of response-adapted therapies aimed to improve the poor outcomes for those patients who remain PET positive."

Writing in a linked Comment, Professor Bruce Cheson, Deputy Chief, Hematology-Oncology and Head of Hematology at Lombardi Comprehensive Cancer Center, Georgetown University, Washington DC, USA, says, "Trotman and colleagues' results might lead to several clinical research opportunities. One such possibility would be to assess if an early reaction to the PET scan result improves patient outcome. Thus, with a positive PET scan after induction therapy could be randomly assigned to either deferred treatment until disease progression or immediate intervention. A preferable alternative would be to introduce a unique agent at that time, such as the newly developed small molecules (eg, idelalisib, ibrutinib, or ABT-199) in a novel combination."

Explore further: PET/CT bests gold standard bone marrow biopsy for diagnosis and prognosis of lymphoma patients

More information: The Lancet Haematology, www.thelancet.com/journals/lan … (14)70008-0/abstract

Related Stories

PET/CT bests gold standard bone marrow biopsy for diagnosis and prognosis of lymphoma patients

August 1, 2013
A more precise method for determining bone marrow involvement in patients with diffuse large B-cell lymphoma (DLBCL)—a key factor in tailoring patient management plans—has been identified by researchers in a study published ...

Bone marrow biopsy adds little to PET/CT staging of Hodgkin's

November 15, 2012
(HealthDay)—For patients with treatment-naive Hodgkin's lymphoma (HL) staged using [18F]fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT), routine bone marrow biopsy (BMB) has little or no therapeutic ...

Study findings question benefit of additional imaging before cancer surgery

May 13, 2014
Among patients with a certain type of colorectal cancer with limited spread to the liver, imaging using positron emission tomography and computed tomography (CT) before surgery did not significantly change the surgical treatment ...

PET/CT shows clear advantages over conventional staging for breast cancer patients

January 2, 2013
New research published in the January issue of The Journal of Nuclear Medicine shows that 18F-fludeoxyglucose (18F-FDG) positron emission tomography (PET)/computed tomography (CT) imaging offers significant prognostic stratification ...

Benefit of PET or PET/CT in oesophageal cancer is not proven

August 28, 2013
The patient-relevant benefit of positron emission tomography (PET) in oesophageal cancer, alone or in combination with computed tomography (CT), is not proven due to a lack of comparative studies. In terms of their diagnostic ...

Recommended for you

New mechanism controlling the master cancer regulator uncovered

November 21, 2018
Who regulates the key regulator? The Research Center for Molecular Medicine of the Austrian Academy of Sciences reports online in the journal Science about a newly discovered mechanism by which RAS proteins, central to cancer ...

Sugar supplement slows tumor growth and can improve cancer treatment

November 21, 2018
Mannose sugar, a nutritional supplement, can both slow tumour growth and enhance the effects of chemotherapy in mice with multiple types of cancer.

Researchers stop spread of cancer in mice by blocking specific molecules

November 21, 2018
Melanoma skin cancer tumors grow larger and are more likely to metastasize due to interactions between a pair of molecules, according to experiments in mice and human cells. The results may restore the potential for a type ...

'Druggable' cancer target found in pathway regulating organ size

November 20, 2018
It's known that cancer involves unchecked cell growth and that a biological pathway that regulates organ size, known at the Hippo pathway, is also involved in cancer. It's further known that a major player in this pathway, ...

A study suggests that epigenetic treatments could trigger the development of aggressive tumours

November 20, 2018
A study headed by the Institute for Research in Biomedicine (IRB Barcelona) and published in the journal Nature Cell Biology examined whether the opening of chromatin (a complex formed by DNA bound to proteins) is the factor ...

Redefining colorectal cancer subtypes

November 20, 2018
There is a long-standing belief that colorectal cancer (CRC), which causes some 50,000 deaths in the United States each year, can be categorized into distinct molecular subtypes. In a paper published recently in the journal Genome ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.